The European Society of Endocrinology has published a new Clinical Practice Guideline for the Management and Evaluation of Menopause and the Perimenopause. The guideline provides guidance on evaluating and managing women with menopause-related symptoms, including hormone therapy benefits and risks. It also discusses alternative treatme...
A novel cofactor engineering approach using phosphite dehydrogenase enables the scalable and efficient biosynthesis of lactate-based copolymers in Escherichia coli. The method yields higher yields of poly(3-hydroxybutyrate-co-lactate) without disrupting bacterial growth, paving the way for sustainable bioplastic manufacturing.
A Phase II clinical trial led by researchers at the University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma. Belzutifan showed a 26% objective response rate, with sustained clinical benefits for those who responded to treatment.
A phase 3 study found that giredestrant plus everolimus significantly improved progression-free survival in patients with ER-positive, HER-2-negative advanced breast cancer. The treatment combination reduced the risk of disease progression or death by 63% in patients with ESR1 mutations.
A randomized trial found that patients with metastatic clear-cell renal carcinoma lived longer without disease progression when treated with lenvatinib and everolimus compared to cabozantinib. The study suggests that lenvatinib plus everolimus may offer a more meaningful benefit as second-line treatment for these patients.
A new class of anti-cancer agents—antibody-drug conjugates (ADCs)—has unveiled compelling evidence that can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer. The phase III DESTINY-Breast05 and DESTINY-Breast11 trials have shown superior efficacy and improved disease-free survival rates, positionin...